Risk-Adapted Adjuvant Chemotherapy After Concomitant Fluoropyrimidine-Radiotherapy Neoadjuvant Treatment for Patients With Resectable CT3-4 or N+ Rectal Cancer: Five-Year Disease-Free Survival Results of a Single-Center Series. (Q41345333)
Jump to navigation
Jump to search
scientific article published on 24 August 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Risk-Adapted Adjuvant Chemotherapy After Concomitant Fluoropyrimidine-Radiotherapy Neoadjuvant Treatment for Patients With Resectable CT3-4 or N+ Rectal Cancer: Five-Year Disease-Free Survival Results of a Single-Center Series. |
scientific article published on 24 August 2015 |
Statements
Risk-Adapted Adjuvant Chemotherapy After Concomitant Fluoropyrimidine-Radiotherapy Neoadjuvant Treatment for Patients With Resectable CT3-4 or N+ Rectal Cancer: Five-Year Disease-Free Survival Results of a Single-Center Series (English)
Javier Sastre
Juan Jose Serrano
Carmen Ramirez
Luis Ortega
Beatriz García-Paredes
Juan Corona
Rosario Alfonso
Sofía Córdoba
24 August 2015